CytoDyn will submit the revised protocol for CD16 providing for a reduction in total enrollment from 330 to 126 patients, with interim efficacy analysis by DSMB after 40% of patients (51 patients) are enrolled and have completed follow-up to Day 28.

Taken from 12/08/21 PR
I recall the cd-17 trial cutting total enrollment in about half to 300 i can’t find on PR maybe mentioned on proactive